Aprea Therapeutics has dosed the first HPV+ head and neck squamous cell carcinoma (HNSCC) patient in Cohort 5 of the ACESOT-1051 trial, evaluating their WEE1 kinase inhibitor APR-1051.
Aprea Therapeutics is progressing its Phase 1 ACESOT-1051 trial of APR-1051, a WEE1 inhibitor, showing promising tolerability in treating cancers with Cyclin E over-expression.
Preliminary data from the phase 1 ACESOT-1051 study indicates that APR-1051, an oral WEE1 inhibitor, is safe and well-tolerated in patients with advanced solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.